ClinicalTrials.gov
ClinicalTrials.gov Menu

Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00789087
Recruitment Status : Completed
First Posted : November 11, 2008
Last Update Posted : November 11, 2008
Sponsor:
Information provided by:
University of Sao Paulo

Brief Summary:
The purpose of this study is to analyze and compare radiological lung expansion after talc pleurodesis performed either by videothoracoscopy or chest tube and correlate it with clinical outcome. Secondary endpoints evaluated were: clinical efficacy, safety, quality of life and survival.

Condition or disease Intervention/treatment Phase
Recurrent Malignant Pleural Effusion. Procedure: Videothoracoscopic talc poudrage (VT). Procedure: Talc slurry through a chest tube (DT). Phase 4

Detailed Description:

Talc pleurodesis is the most popular method to control symptoms of recurrent malignant pleural effusion. The intrapleural talc delivery may be by videothoracoscopy and talc poudrage or talc slurry thought a chest tube and the best method is still controversial. Although the lung expansion is a key criteria for success of the procedure, its characteristics are poorly studied.

Patients were enrolled into two groups: videothoracoscopic talc poudrage (VT) and talc slurry through a chest tube (DT). Lung expansion was evaluated through chest CT scans obtained obtained in the first 7 days and 1, 3 and 6 months after pleurodesis. All examinations were revised by two independent observers. Clinical efficacy (considered as lack of new procedures during follow up), complications, drainage duration, hospital stay and quality of life (general and specific questionnaires) were also analyzed.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Analysis of Clinical and Radiological Results of Two Methods of Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion
Study Start Date : January 2005
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Arm Intervention/treatment
Active Comparator: 1. Videothoracoscopic talc poudrage (VT) Procedure: Videothoracoscopic talc poudrage (VT).
Videothoracoscopic talc poudrage
Other Name: Videothoracoscopic talc poudrage

Active Comparator: 2. Talc slurry through a chest tube (DT) Procedure: Talc slurry through a chest tube (DT).
Talc slurry through a chest tube
Other Name: Talc slurry through a chest tube




Primary Outcome Measures :
  1. Radiological lung expansion after talc pleurodesis and clinical outcome [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Clinical efficacy, safety, quality of life and survival. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Malignant pleural effusion confirmed by cytological analysis of pleural fluid and/or pleural biopsy;
  • Recurrent pleural effusion with symptoms;
  • Chest radiography with lung expansion after thoracocentesis;
  • Karnofsky Performance Status > 70;
  • Written informed patient consent were obtained.

Exclusion Criteria:

  • Hemorrhagic diathesis;
  • Active infection;
  • Cutaneous infiltration;
  • Patients unable to understand the questionnaires;
  • Age: > 90 yo or < 18 yo.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00789087


Locations
Brazil
University of São Paulo Medical School
São Paulo, Brazil, 01246903
Sponsors and Collaborators
University of Sao Paulo
Investigators
Principal Investigator: Ricardo M. Terra, MD University of Sao Paulo

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ricardo M. Terra, University of São Paulo Medical School
ClinicalTrials.gov Identifier: NCT00789087     History of Changes
Other Study ID Numbers: 1105/04
First Posted: November 11, 2008    Key Record Dates
Last Update Posted: November 11, 2008
Last Verified: November 2008

Keywords provided by University of Sao Paulo:
Pleural Effusion.
Talc.
Pleurodesis.
Quality of Life.
Thoracoscopy.

Additional relevant MeSH terms:
Pleural Effusion
Pleural Effusion, Malignant
Pleural Diseases
Respiratory Tract Diseases
Pleural Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms